New method shortcut in drug development

July 11, 2017
Credit: Susan Buck Ms/Public Domain

In the latest issue of the journal Proceedings of the National Academy of Sciences (PNAS), a research group at Uppsala University presents a new, small-scale method that may become a smart shortcut for determining the bioavailability of a pharmaceutical drug within cells.

"Finding out how a therapeutic affects the body means having to consider many different factors that can influence the cells' internal environment. Our may be a way of substantially facilitating this stage," says Professor Per Artursson.

The researcher led the joint study underway with colleagues at the Chemical Biology platform in SciLifeLab (created jointly by Uppsala and Stockholm Universities, Karolinska Institute and KTH Royal Institute of Technology) and GlaxoSmithKline in Stevenage, UK.

The majority of promising new drug candidates are effective only within the cells, but quick general methods of determining intracellular drug quantities are lacking. A team of researchers headed by the Drug Delivery Group at Uppsala University may now be on the track of a solution through a fast, small-scale method of determining a drug's bioavailability (the fraction available to work in biological processes) inside cultured cells. By measuring the unbound quantity of the drug in the cells, the method accounts for the drug partly "disappearing" when it binds to cell components where it cannot exert its intended effect. This "disappearing" proportion of the drug varies from one molecule to another and has hitherto been hard to predict, but can now be easily determined with the researchers' small-scale method.

The research group has also demonstrated that, measured with the new method, bioavailability can be used to predict the effects of the drug molecules in more advanced cell models for specific therapeutic areas such as cancer, inflammation and dementia disorders.

"It takes time to develop models for specific therapeutic areas, so our method may be especially useful in early stages of drug development. Major pharmaceutical drug companies have already shown great interest and the method is now being offered on the SciLifeLab Drug Discovery and Development platform," Artursson says.

The scientists are currently investigating whether the method can predict effects of drugs in the body, as well. This is more complicated than a cell culture. Since taking blood samples is simple while sampling tissue is considerably more difficult, bioavailability is often predicted on the basis of drug concentrations in the blood – a fairly blunt instrument.

The proportion of a drug entering the target cell may be either higher or lower than in the blood. The drug may, for example, bind to the cell's fat molecules, break down, or be transported out of the cell. These mechanisms reduce the available fraction of the drug inside the cell, i.e. its intracellular bioavailability. Retrospective correction factors must therefore often be introduced to allow for these mechanisms in the use of "pharmacokinetic models" to study a drug's route of administration into the body.

"Our preliminary studies show that replacing the correction factors with a simple determination of local bioavailability in the seems to be possible. But more experiments are required before we know how applicable our principle is at tissue and organism level. Clearly, intracellular is on the way to becoming an important early instrument in research," Artursson says.

"Prediction of intracellular exposure bridges the gap between target- and cell-based drug discovery," PNAS (Proceedings of the National Academy of Sciences, will be published online this week, 10-14 July 2017.

Explore further: Improved accuracy for cancer drug testing

More information: Mateus et al; Prediction of intracellular exposure bridges the gap between target- and cell-based drug discovery, PNAS www.pnas.org/cgi/doi/10.1073/pnas.1701848114

Related Stories

Improved accuracy for cancer drug testing

June 14, 2017
A method to more accurately test anti-cancer drugs has now been developed at the Sahlgrenska Academy, University of Gothenburg. The method paves the way to much earlier assessment of who benefits from a specific drug and ...

FDA approves first new drug in 20 years for sickle cell

July 7, 2017
The U.S. Food and Drug Administration has approved the first drug in nearly 20 years for sickle cell, an inherited disease in which abnormally shaped red blood cells can't properly carry oxygen throughout the body, which ...

New model can predict drug interactions and side effects even between a large number of components

April 10, 2017
Drug cocktails such as those for treating cancer, like the alcoholic versions offered at the local bar, are best when the proper ingredients are mixed in the right proportions. And like the cocktails we normally drink, the ...

Recommended for you

Hibernating ground squirrels provide clues to new stroke treatments

November 17, 2017
In the fight against brain damage caused by stroke, researchers have turned to an unlikely source of inspiration: hibernating ground squirrels.

Molecular guardian defends cells, organs against excess cholesterol

November 16, 2017
A team of researchers at the Harvard T. H. Chan School of Public Health has illuminated a critical player in cholesterol metabolism that acts as a molecular guardian in cells to help maintain cholesterol levels within a safe, ...

Prototype ear plug sensor could improve monitoring of vital signs

November 16, 2017
Scientists have developed a sensor that fits in the ear, with the aim of monitoring the heart, brain and lungs functions for health and fitness.

Ancient enzyme could boost power of liquid biopsies to detect and profile cancers

November 16, 2017
Scientists are developing a set of medical tests called liquid biopsies that can rapidly detect the presence of cancers, infectious diseases and other conditions from only a small blood sample. Researchers at The University ...

FDA to crack down on risky stem cell offerings

November 16, 2017
U.S. health authorities announced plans Thursday to crack down on doctors pushing stem cell procedures that pose the gravest risks to patients amid an effort to police a burgeoning medical field that previously has received ...

Engineering the gut microbiome with 'good' bacteria may help treat Crohn's disease

November 15, 2017
Penn Medicine researchers have singled out a bacterial enzyme behind an imbalance in the gut microbiome linked to Crohn's disease. The new study, published online this week in Science Translational Medicine, suggests that ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.